| Literature DB >> 29133822 |
HangTong Hu1, Qiao Zheng1, Yang Huang1, Xiao Wen Huang1, Zhi Cheng Lai1, JingYa Liu1, XiaoYan Xie1, Shi Ting Feng2, Wei Wang3, Ming De Lu1,4.
Abstract
Microvascular invasion (MVI) is rarely diagnosed preoperatively in hepatocellular carcinoma (HCC). The aim of this meta-analysis is to assess the diagnostic power of a non-smooth tumor margin on preoperative imaging for MVI. We performed a literature search using the PubMed, Embase and Cochrane Library databases, and 11 studies were included involving 618 MVI-positive cases and 1030 MVI-negative cases. Considerable heterogeneity was found, and was indicated to be attributable to the mean patient ages in the included studies. In subgroups of studies with a mean patient age older than 60 years and studies with computed tomography (CT) as the imaging method (as opposed to magnetic resonance imaging (MRI)), heterogeneity was low, and the diagnostic odds ratio (DOR) of the single two-dimensional imaging feature for MVI was 21.30 (95% CI [12.52, 36.23]) and 28.78 (95% CI [13.92, 59.36]), respectively; this power was equivalent to or greater than that of certain multivariable-based scoring systems. In conclusion, a non-smooth tumor margin on preoperative imaging is of great value for MVI assessment and should be considered for inclusion in future scoring systems.Entities:
Mesh:
Year: 2017 PMID: 29133822 PMCID: PMC5684346 DOI: 10.1038/s41598-017-15491-6
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Flow chart diagram presenting the selection of eligible studies.
Characteristics of the 11 included studies.
| Study | Year | Country | Patients(Tumors) (n) | Age | Imaging methods | P (non-smooth) (%) | TP | FP | FN | TN | QUADAS Score |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Kim | 2009 | Korea | 66(70) | 55 | MR | 39 | 19 | 8 | 16 | 27 | 11 |
| Ariizumi | 2011 | Japan | 61(61) | 67 | MR | 39 | 10 | 14 | 1 | 36 | 9 |
| Chou | 2012 | China | 102(102) | 60 | CT | 39 | 33 | 7 | 17 | 45 | 13 |
| Witjes | 2012 | Netherlands | 64(64) | 56 | MR | 28 | 14 | 4 | 31 | 15 | 6 |
| Chou | 2014 | China | 102(102) | 63 | CT | 53 | 49 | 5 | 11 | 37 | 12 |
| Xu | 2014 | China | 109(109) | 53 | MR | 18 | 8 | 12 | 31 | 58 | 13 |
| Ahn | 2015 | Korea | 51(78) | 52 | MR | 40 | 11 | 20 | 7 | 40 | 11 |
| Lei | 2016 | China | 707(707) | 52 | MR | 17 | 33 | 90 | 178 | 406 | 10 |
| Renzulli | 2016 | Italy | 125(140) | 62 | CT/MR | 59 | 75 | 8 | 15 | 42 | 8 |
| Wu | 2016 | Japan | 79(79) | 70 | CT/MR | 38 | 13 | 17 | 2 | 47 | 9 |
| Yang | 2016 | China | 136(136) | 56 | MR | 39 | 24 | 29 | 20 | 63 | 7 |
Patients (Tumors) (n): TP, FP, FN and TN referred to tumor number. Number outside the bracket was that of patients, and inside the bracket was that of tumor number; MR: Magnetic Resonance Imaging; CT: Computed Tomography; P (non-smooth) (%): percentage of patients with a non-smooth tumor margin on preoperative imaging test; TP: true-positive, FP: false-positive, FN: false-negative, TN: true-negative.
Figure 2Quality of included studies according to QUADAS-2 guidelines. Risk of bias and applicability concerns of each included study. Proportion of studies with risk of bias; proportion of studies with regarding applicability. The risk bias mainly raised from patient selection due to inappropriate inclusion and exclusion, and determined as “high”. Another source of bias was indefinite report of blind method and interval between imaging and MVI pathological detection, and determined as “unclear”.
Pooled results of subgroup analysis.
| Category | SEN[95%CI] | SPE[95%CI] | PLR[95%CI] | NLR[95%CI] | DOR[95%CI] | AUC | |
|---|---|---|---|---|---|---|---|
| Age (mean) | ≥60 | 0.81[0.72, 0.89] | 0.81[0.73, 0.87] | 4.14[2.99, 5.74] | 0.25[0.17, 0.37] | 21.30[12.52, 36.23] | 0.90 |
| <60 | 0.37[0.23, 0.54] | 0.76[0.70, 0.81] | 1.47[1.03, 2.09] | 0.82[0.67, 1.01] | 1.84[1.02, 3.34] | 0.72 | |
| Imaging | CT | 0.75[0.65, 0.82] | 0.87[0.79, 0.93] | 5.66[3.29, 9.74] | 0.29[0.16, 0.55] | 19.42[7.53, 50.16] | — |
| MR | 0.30[0.25, 0.34] | 0.78[0.75, 0.81] | 1.68[1.12, 2.53] | 0.79[0.62, 0.99] | 2.25[1.15, 4.38] | 0.74 | |
| P (non-smooth) (%) | ≥53 | 0.83[0.76, 0.88] | 0.86[0.77, 0.92] | 5.77[3.47, 9.59] | 0.20[0.14, 0.29] | 28.78[13.92, 59.36] | — |
| <53 | 0.35[0.31, 0.40] | 0.79[0.76, 0.81] | 2.03[1.36, 3.03] | 0.65[0.48, 0.88] | 3.51[1.62, 7.58] | 0.79 | |
SEN: sensitivity; SPE: specificity; PLR: positive likelihood ratio; NLR: negative likelihood ratio; DOR: diagnostic odds ratio; AUC: area under the receiver operating characteristic curve.
Figure 3Forest plots of sensitivity and exact 95% confidence interval for subgroups of age ≥ 60 and age <60. CI: confidence interval. TP: true-positive, FP: false-positive, FN: false-negative, TN: true-negative. The summary sensitivity was 0.81[0.72, 0.89] for the subgroup of age older than 60, and 0.37[0.23, 0.54] for that of age younger than 60.
Figure 4Forest plots of specificity and exact 95% confidence interval for subgroups of age ≥ 60 and age <60. CI: confidence interval. TP (true-positive), FP (false-positive), FN (false-negative), TN (true-negative). The summary specificity was 0.81[0.73, 0.87] for the subgroup of age older than 60, and 0.76[0.70, 0.81] for that of age younger than 60.
Comparisons with multivariable based scoring system.
| Items | Factors | Category | SEN | SPE | PLR | NLR | DOR | AUC |
|---|---|---|---|---|---|---|---|---|
| Non-smooth tumor margin | Single factor | Age < 60 | 0.81 | 0.81 | 4.14 | 0.25 | 21.30 | 0.90 |
| CT | 0.75 | 0.87 | 5.66 | 0.29 | 19.42 | — | ||
| Lei | Tumor size + Tumor number + AFP + HBV DNA load + PLT + Typical dynamic pattern + Tumor capsule | Age = 52 | 0.62 | 0.81 | 3.20 | 0.47 | 7.0^ | 0.80 |
| Liu | AFP + miR125b | Age = 54 | 0.84 | 0.72 | 3.00^ | 0.22^ | 13.5^ | 0.87 |
| Miyata | T1 ring + AP shunt + Distortion of corona | Age = 67 | 0.82 | 0.84 | 5.13^ | 0.21^ | 23.9^ | — |
| Shirabe | Tumor size + DCP + Tumor grade | Age = 61 | 0.75 | 0.85 | 5.00^ | 0.29^ | 17.0^ | — |
| You | Tumor size + AFP + Hypersplenism | Age = 50 | 0.76 | 0.75 | 3.04^ | 0.32^ | 9.50^ | 0.79 |
| Zhao | AFP + GGT + Tumor size + Tumor number | Age = 50 | 0.82 | 0.83 | 4.8 | 0.2 | 22.24^ | 0.86 |
^Data was obtained by estimation with SEN and SPE by DOR = SEN*SPE/(1-SEN)/(1-SPE), or PLR = SEN/(1-SPE), or NLR = (1-SEN)/SPE.